Compare INCR & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INCR | ICCC |
|---|---|---|
| Founded | 1994 | 1982 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 55.5M |
| IPO Year | 2021 | 1995 |
| Metric | INCR | ICCC |
|---|---|---|
| Price | $0.77 | $6.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 47.3K | 11.6K |
| Earning Date | 03-30-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.33 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | $69.54 | N/A |
| Revenue Next Year | $41.75 | N/A |
| P/E Ratio | ★ N/A | $30.20 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $0.68 | $4.52 |
| 52 Week High | $1.77 | $7.60 |
| Indicator | INCR | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 32.81 | 46.64 |
| Support Level | $0.68 | $6.06 |
| Resistance Level | $0.88 | $6.85 |
| Average True Range (ATR) | 0.03 | 0.21 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 24.29 | 38.01 |
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.